Form 13-F position report

REVOLUTION MEDICINES INC

Reported by Frazier Life Sciences Management L P

RVMD CUSIP 76155X100 Manager CIK 0001892134

Reported 997,455 shares, unchanged from the prior quarter.

Reported value 4.0%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 1.47% This manager · Q2 2025
Shares 997,455 Quarter-end amount reported
Reported value $36,696,369 Fair value at quarter end
Consecutive quarters held 10 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-03-31 18508123
2023-06-30 22857447
2023-09-30 27609554
2023-12-31 28607009
2024-03-31 32147975
2024-06-30 38711229
2024-09-30 45234584
2024-12-31 43628682
2025-03-31 35270009
2025-06-30 36696369
2025-09-30 46581149
2025-12-31 63517291
2026-03-31 65710464
2026-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for REVOLUTION MEDICINES INC held by Frazier Life Sciences Management L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 0 -675,686 (-100.0%) 0 $0 2026-08-14
Q1 2026 Reduced 675,686 -121,769 (-15.3%) 1.69% $65,710,464 2026-05-15
Q4 2025 Reduced 797,455 -200,000 (-20.1%) 1.71% $63,517,291 2026-02-13
Q3 2025 Unchanged 997,455 0 (0.0%) 1.4% $46,581,149 2025-11-14
Q2 2025 Unchanged 997,455 0 (0.0%) 1.47% $36,696,369 2025-08-14
Q1 2025 Unchanged 997,455 0 (0.0%) 1.61% $35,270,009 2025-05-15
Q4 2024 Unchanged 997,455 0 (0.0%) 1.81% $43,628,682 2025-02-18
Q3 2024 Unchanged 997,455 0 (0.0%) 1.81% $45,234,584 2024-11-15
Q2 2024 Unchanged 997,455 0 (0.0%) 1.81% $38,711,229 2024-08-15
Q1 2024 Unchanged 997,455 0 (0.0%) 1.36% $32,147,975 2024-05-15
Q4 2023 Unchanged 997,455 0 (0.0%) 1.53% $28,607,009 2024-02-14
Q3 2023 Added 997,455 +142,971 (16.7%) 1.83% $27,609,554 2023-11-14
Q2 2023 Unchanged 854,484 0 (0.0%) 1.37% $22,857,447 2023-08-14
Q1 2023 New 854,484 +854,484 (0.0%) 1.34% $18,508,123 2023-05-15

Who else reported the position

343 managers reported REVOLUTION MEDICINES INC for Q2 2025.

Managers reporting REVOLUTION MEDICINES INC in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Reduced 15,761,691 -850,344 < 0.01% $579,872,613 22 qtrs
FARALLON CAPITAL MANAGEMENT LLC Added 14,325,692 +791,000 2.21% $527,042,209 18 qtrs
JANUS HENDERSON GROUP PLC Added 10,590,727 +400,656 0.19% $389,682,579 11 qtrs
WELLINGTON MANAGEMENT GROUP LLP Reduced 10,259,738 -1,528,183 0.07% $377,455,760 22 qtrs
BAKER BROS ADVISORS LP Added 9,364,972 +1,428,000 3.34% $344,537,320 18 qtrs
BlackRock Inc Reduced 8,661,393 -6,030,999 < 0.01% $318,652,648 4 qtrs
FMR LLC Added 8,325,184 +789,413 0.02% $306,283,536 22 qtrs
Nextech Invest Ltd Unchanged 7,601,087 0 52.92% $279,643,991 2 qtrs
Paradigm Biocapital Advisors LP Reduced 6,093,291 -84,820 9.57% $224,172,176 6 qtrs
BVF INC IL Unchanged 4,982,384 0 6.55% $183,301,907 22 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
997,455
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.